食管癌的靶向治疗概述

Bregni Giacomo, Beck Benjamin

Institut Jules Bordet, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium.

Welbio and FNRS Investigator at IRIBHM, Faculty of Medicine, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium.

Cancers (Basel). 2022 Mar 16;14(6):1522. doi: 10.3390/cancers14061522.

Oesophageal cancer is one of the leading causes of cancer-related death worldwide. Oesophageal cancer occurs as squamous cell carcinoma (ESCC) or adenocarcinoma (EAC). Prognosis for patients with either ESCC or EAC is poor, with less than 20% of patients surviving more than 5 years after diagnosis. A major progress has been made in the development of biomarker-driven targeted therapies against breast and lung cancers, as well as melanoma. However, precision oncology for patients with oesophageal cancer is still virtually non-existent. In this review, we outline the recent advances in oesophageal cancer profiling and clinical trials based on targeted therapies in this disease.

食管癌是全球癌症相关死亡的主要原因之一。食管癌分为鳞状细胞癌（ESCC）或腺癌（EAC）。ESCC或EAC患者的预后都很差，诊断后存活超过5年的患者不到20%。在针对乳腺癌、肺癌以及黑色素瘤的生物标志物驱动的靶向治疗开发方面已经取得了重大进展。然而，食管癌患者的精准肿瘤学实际上仍然不存在。在这篇综述中，我们概述了食管癌分析以及基于该疾病靶向治疗的临床试验的最新进展。